article thumbnail

How AI will reshape pharma by 2025

Drug Target Review

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Looking ahead, 2025 could represent a major turning point for the pharmaceutical sector.

article thumbnail

Drug Discovery Informatics for Big Pharma: Key Webinar Insights

Collaborative Drug

The pharmaceutical R&D landscape continues to evolve rapidly with advances in computational technologies and artificial intelligence.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Collaborative Drug Discovery and deepmirror Announce Collaboration for Humanitarian and Commercial Drug Discovery

Collaborative Drug

BURLINGAME, Calif. July 8, 2025.

article thumbnail

CDMO Selection: The Ultimate Checklist

Drug Patent Watch

This growth has created a competitive landscape where pharmaceutical companies must carefully evaluate and select the right CDMO partner to ensure the success of their projects. Pharmaceutical companies should look for CDMOs with a proven track record of working with various molecules and pharmaceutical companies.

article thumbnail

GSK to buy liver disease drug for $1.2B

BioPharma Drive: Drug Pricing

The new acquisition from Boston Pharmaceuticals adds to a wave of dealmaking undertaken by GSK to build its liver disease franchise.

article thumbnail

The Role of Artificial Intelligence (AI) and Machine Learning (ML) in Drug Repurposing

Drug Patent Watch

In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).

article thumbnail

Bristol Myers, Pfizer to offer Eliquis at a discount for some patients

BioPharma Drive: Drug Pricing

The program is the latest example of pharmaceutical companies bypassing traditional drug distribution channels for people who aren’t insured or are willing to pay cash for their medications.